Novo Nordisk Offers Discounted Wegovy Subscriptions

Novo Nordisk is introducing a discounted subscription plan for self-pay patients in the U.S. seeking Wegovy, with monthly costs potentially up to 30% lower than the standard rate. This initiative aims to broaden access to the popular obesity drug and compete more effectively against rival Eli Lilly. By offering a more affordable option, Novo Nordisk seeks to capture a larger share of the rapidly growing market for weight-loss medications. The subscription model represents a strategic effort to enhance patient affordability and market penetration.